Unlocking the Potential of NDUFA9 as a Drug Target and Biomarker

Target Name: NDUFA9

NCBI ID: G4704

NDUFA9

Unlocking the Potential of NDUFA9 as a Drug Target and Biomarker

NADH (nicotinamide adenine dinucleotide) is a crucial coenzyme found in all living cells that plays a pivotal role in energy metabolism. NAD+ is a dinucleotide, consisting of two nucleotides joined together, and it has a central carbon atom that is reversibly reduced to form NADH. NADH is an essential coenzyme for the transfer of electrons in the electron transport chain of the cell during processes such as cellular respiration, and it is also an electron carrier in the production of ATP from ADP.

TheNDUFA9 protein is a unique enzyme that is involved in the catalytic process of NADH dehydrogenase (NDUFA9), a critical enzyme in the electron transport chain of the cell. TheNDUFA9 protein is a member of the ubiquinone family and is responsible for the conversion of NADH to NAD+. This conversion is crucial for the production of ATP from ADP during cellular respiration.

TheNDUFA9 protein has been identified as a potential drug target and biomarker due to its unique function in energy metabolism. The development of new therapeutic strategies for theNDUFA9 protein has the potential to treat a range of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

The Structure and Function of NDUFA9

TheNDUFA9 protein is a 23 kDa protein that consists of 114 amino acid residues. It has a characteristic Rossmann-fold that is typical of the ubiquinone family of proteins. The Rossmann-fold is a structural motif that is found in the core of many proteins and is responsible for the protein's stability and functions.

TheNDUFA9 protein has a single function, which is to catalyze the conversion of NADH to NAD+. This conversion occurs through a series of distinct substrate-binding events that involve the transfer of electrons from NADH to theNDUFA9 protein. TheNDUFA9 protein uses a unique substrate-binding mechanism that involves a unique N-terminal extension that is specific to NADH.

TheNDUFA9 protein has been shown to be a critical enzyme in the electron transport chain of the cell. It has been shown to have a high affinity for NADH and to catalyze the conversion of NADH to NAD+ at a rate of 260 nM. This conversion rate is much higher than that of other NADH enzymes, such as the NAD+-dependent enzymes that are found in bacteria and yeast.

TheNDUFA9 protein has also been shown to have a unique mechanism of substrate binding that is specific to NADH. The protein has a unique N-terminal extension that is specific to NADH and allows it to bind to the substrate with high affinity. This mechanism may be important for theNDUFA9 protein's unique function in energy metabolism.

The Potential of NDUFA9 as a Drug Target

TheNDUFA9 protein has been identified as a potential drug target due to its unique function in energy metabolism. The development of new therapeutic strategies for theNDUFA9 protein has the potential to treat a range of diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

One of the potential therapeutic strategies for theNDUFA9 protein is the use of small molecules that can inhibit the activity of the NDUFA9 protein. This can be done by binding to the protein's active site, which is the site where the protein binds to NADH and NAD+. This can lead to a reduction in the rate of NADH dehydrogenase and a decrease in the production of NAD+.

Another potential therapeutic strategy for theNDUFA9 protein is the use of antibodies that can specifically bind to the protein. This can lead to the inhibition of

Protein Name: NADH:ubiquinone Oxidoreductase Subunit A9

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Required for proper complex I assembly (PubMed:28671271). Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

The "NDUFA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets